Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Jacobs on the Use of Ibrutinib in High-Risk Patients With CLL

Ryan W. Jacobs, MD
Published: Thursday, Apr 26, 2018



Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

When a clinician does a work up and looks at the genes of patients with high-risk prognosis using FISH analyses and IGHV analyses, they know that these patients do worse with chemo-immunotherapy. The patients with deletion 17p, 11q, trisomy 12, and unmutated IGHV have less return on historical treatments.

However, this particular group of patients seem to show more benefit with ibrutinib. The data backing the agent seems to level the playing field, says Jacobs. The patients with 11q found by FISH seem to do just as well as the patients without 11q deletion, and the patients with unmutated IGHV seem to do just as well as the patients with an IGHV mutation.
 


Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

When a clinician does a work up and looks at the genes of patients with high-risk prognosis using FISH analyses and IGHV analyses, they know that these patients do worse with chemo-immunotherapy. The patients with deletion 17p, 11q, trisomy 12, and unmutated IGHV have less return on historical treatments.

However, this particular group of patients seem to show more benefit with ibrutinib. The data backing the agent seems to level the playing field, says Jacobs. The patients with 11q found by FISH seem to do just as well as the patients without 11q deletion, and the patients with unmutated IGHV seem to do just as well as the patients with an IGHV mutation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x